tbuckley/cabot-search huggingface dataset:
Deaths
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies.
Authors: Justine Yang Bruce, Hans Hammers, Jill Kolesar, Mark N. Stein, Jens C. Eickhoff, Lakeesha Carmichael, Susan Johnston, Scott Perlman, Robert Jeraj, Glenn Liu
Journal: Journal of Clinical Oncology (2013)

434 Background: Su treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of Su results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Higher flare corresponded to shorter PFS. Concurrent Su plus Bev is poorly tolerated with high (37%) incidence of microangiopathic hemolytic anemia (MAHA). Based on biological rationale and to improve the toxicity profile, we evaluated a sequential design administering Bev during the Su treatment break. We planned to evaluate the ability of Bev to suppress the Su withdrawal flare using FLT PET/CT. Methods: Pts with no prior VEGF treatment were enrolled in this multi-institutional study. All pts had target lesions amenable to serial FLT PET/CT imaging. Su was given at 37.5 mg on day 1-28 every 6 weeks with Bev 5 mg/kg on day 29. If safe and tolerable, Su would increase to 50 mg. Once the Su dose was established, FLT PET/CT scans would be obtained at baseline (D1), week 4, and week 6 to evaluate pharmacodynamics of the sequential combination. Su pharmacokinetics and total, free, and bound VEGF levels were obtained on each cycle at D1, pre-Bev (D29), 4 hours post Bev (D29H4) and day 42 (D42). Results: Six pts enrolled in the safety cohort of Su 37.5 mg plus Bev. One pt experienced gr 1 MAHA and after discussion with CTEP, the trial was closed to further accrual. No imaging scans were obtained due to early closure. Data assessing VEGF dynamics appears in the table. Conclusions: Subclinical MAHA was seen despite using sequential Su with low dose Bev and this combination was not feasible for further development. As predicted, VEGF levels increased during Su exposure followed by a rapid decline after Bev. Due to the long half-life of Bev, we expected VEGF ligand suppression through D42, but instead observed a complete rebound in total/free VEGF levels by D42. VEGF ligand production may be increased as a result of Bev, implying a robust host compensatory mechanism to VEGF signaling pathway inhibition. A greater understanding of the compensatory mechanism would aid future sequencing strategies of new agents. Clinical trial information: NCT01243359. [Table: see text]
Canadian Medical Association Journal, Toronto
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Attenti Alle Bufale (‘Beware of Red Herrings’), or, How to Make Evidence-Based Medicine Work for You
Authors: Tom Jefferson, Lucia Zarra, Liviu Stoica
Journal: Journal of the Royal Society of Medicine (2006)

This is the first in a series of articles on making evidence-based medicine work for you. The series is based on the book ‘Attenti Alle Bufale’ by Tom Jefferson.
FDA Participates in Clinical Laboratory Improvement Regulations
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
O: Oral presentations
Authors: A Occhialini, M Urdaci, F Doucet-Populaire, H Lamouliatte, C B6bear, F Megraud, G Perez-P6rez, R Carmel, M Blaser
Journal: Gut (1996)

Resistance of Helicobacter pylori to macrolides is a major cause of treatment failure of eradication therapies.A princeps work based on U.S. strains showed that this resistance was due to a point mutation on the gene coding for the 23S ribosomal RNA of H. pylori.Our goal was to extend this work using European strains, to test the consequence of this mutation on erythromycin binding to H. pylori ribosomes, and to find a quick method to detect this mutation.The reference strain CIP 101260 and 7 pairs of H. pylori strains were used, the parent strain being susceptible to macrolides, and a second strain having acquired resistance in vivo during clarithromycin treatment.The identity of the strains was confirmed by RAPD using 2 primers.The MIC values were measured by E test and agar dilution method.Amplification was carried out on the peptidyl transferase loop region of the gene coding for the 23S rRNA using appropriate primers in order to confirm the presence of the mutations 2058, 2059 and 2611 previously described.The amplified products were sequenced.Erythromycin binding was tested on purified ribosomes isolated from one pair of strains using 14C labelled erythromycin.A point mutation was found on resistant strains at position 2058 (3 cases) and 2059 (4 cases) but never on the opposite DNA fragment of domain V of the gene.The mutation was A--~G in all except one case (A->C) in position 2058.Erythromycin binding increased in a dose dependent manner for the susceptible strain but not for the resistant one.Using BsaI and BbsI restriction enzymes on the amplified products, we could confirm the mutations in positions 2059 and 2058, respectively.In conclusion, the same mutations as previously found were present in European strains.This mutation correlates with a decreased uptake of macrolide by ribosomes.Finally the mutation could be detected without se- quencing by performing PCR-RFLP using appropriate restriction enzymes.
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease
Authors: Stephen P. Fortmann, Earl Ford, Michael H. Criqui, Aaron R. Folsom, Tamara B. Harris, Yuling Hong, Thomas A. Pearson, David Siscovick, Frank Vinicor, Peter F. Wilson
Journal: Circulation (2004)

This article summarizes epidemiological studies of inflammation markers, particularly C-reactive protein, and cardiovascular disease as of early 2002. Gaps in the research and the public health practice implications are also discussed. Although considerable work has been published since this review was completed, the perspectives and issues presented are still useful in evaluating the use of inflammation markers for risk stratisfication and prevention.
Hybridomas in Biotechnology and Medicine—Course
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Hybridomas in Biotechnology and Medicine—Course Get access JNCI: Journal of the National Cancer Institute, Volume 75, Issue 4, October 1985, Page 799, https://doi.org/10.1093/jnci/75.4.799-c Published: 01 October 1985
Owen H. Wangensteen, MD, PhD, dead at 82
Authors: M. Preston
Journal: JAMA (1981)

Owen H. Wangensteen, MD, PhD, teacher, researcher, and surgeon, died of a myocardial infarction at Abbott-Northwestern Hospital in Minneapolis on Jan 13. He was 82 years old. Wangensteen was chief of surgery at the University of Minnesota Hospital for almost 40 years. Perhaps best remembered for the now-famous "Wangensteen tube" that facilitates conservative management of bowel obstruction with suction applied to an indwelling duodenal tube, he will also be remembered for his contributions in the treatment of stomach cancer. Wangensteen was born on a small farm in Lake Park, Minn, in September 1898. Because of his interest in farm animals, he aspired to become a veterinarian. However, after auditing a surgical lecture, he changed his mind. He earned all his degrees at the University of Minnesota. At age 31, Wangensteen was selected to head the Department of Surgery at the university—a position he held until he retired in 1967. Truly
OC-017 Autofluorescence-targeted Optical Biopsy Accurately Diagnoses Dysplasia In Barrett’s Oesophagus And Can Detect The Field Of Molecular Change
Authors: M Di Pietro, E Bird-Lieberman, X Liu, M O’Donovan, R Fitzgerald
Journal: Gut (2014)

<h3>Introduction</h3> Probe-based confocal laser endomicroscopy (pCLE) allows optical biopsies in Barrett’s oesophagus (BO) to predict histological outcome but it is subject to sampling error if performed in a random fashion. We used autofluorescence imaging (AFI) to direct pCLE and added molecular biomarkers to the histopathological diagnosis. The aims of this study were to assess the diagnostic accuracy for dysplasia of AFI-targeted optical biopsies and to investigate the correlation between pCLE patterns and field of molecular change. <h3>Methods</h3> 46 patients with BO (non-dysplastic BE n = 20, indefinite for dysplasia n = 4, low grade dysplasia n = 10, high grade dysplasia (HGD) or intramucosal cancer (IMC) n = 12) were recruited at a single centre. Patients underwent high-resolution endoscopy followed by AFI and then pCLE was performed on AFI positive (AFI+) areas. Targeted biopsies were taken from AFI+ areas, followed by random biopsies as per Seattle protocol. pCLE sequences were graded according to published criteria. Cyclin A and p53 expression were assessed by immunohistochemistry and aneuploidy by flow-cytometry on AFI-targeted biopsies. Statistical analyses were performed using chi-square test. <h3>Results</h3> AFI-targeted pCLE correctly classified all the HGD/EC patients and had a sensitivity and specificity for any grade of dysplasia of 93 and 83%, respectively. The Seattle protocol had similar sensitivity for HGD/IMC and any grade of dysplasia (83 and 89%, respectively). For the per-location analysis, a total of 155 endoscopic areas were analysed with pCLE and molecular biomarkers. pCLE had a sensitivity and a specificity for HGD/IMC and any grade of dysplasia of 100/64% and 78/75%, respectively. Overall, 40% of pCLE irregular sequences corresponded to non-dysplastic areas (false positive). We found a statistically significant enrichment (p &lt; 0.001) of the three molecular biomarkers in pCLE irregular areas (Figure 1). After exclusion of dysplastic areas, a significant correlation between pCLE irregularity and biomarker positivity was retained (p = 0.008). The presence of at least 1 positive biomarker significantly correlated with dysplasia both in pCLE irregular (p = 0.01) and pCLE regular areas (p = 0.05). <h3>Conclusion</h3> AFI-targeted pCLE has a high diagnostic accuracy for dysplasia in BO. Tissue biomarkers are a useful adjunct to characterise the field of molecular abnormality associated with optical dysplasia. These results suggest that the presence of pCLE irregularity, even in the absence of histological dysplasia, relates to molecular changes and may warrant close follow up. <h3>Disclosure of Interest</h3> None Declared.
Molecular Machines
Authors: C. Mavroidis, A. Dubey, M.L. Yarmush
Journal: Annual Review of Biomedical Engineering (2004)

Molecular machines are tiny energy conversion devices on the molecular-size scale. Whether naturally occurring or synthetic, these machines are generally more efficient than their macroscale counterparts. They have their own mechanochemistry, dynamics, workspace, and usability and are composed of nature's building blocks: namely proteins, DNA, and other compounds, built atom by atom. With modern scientific capabilities it has become possible to create synthetic molecular devices and interface them with each other. Countless such machines exist in nature, and it is possible to build artificial ones by mimicking nature. Here we review some of the known molecular machines, their structures, features, and characteristics. We also look at certain devices in their early development stages, as well as their future applications and challenges.
Philosophy of Biology
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Circumcision.
Authors: C M Ridley, S M Neill
Journal: BMJ (1993)

sampling strategies may under-represent minori- ties with multiple partners (for example, prosti- tutes); and sexual partnerships occur outside the sampled population through migration and travel.Women have male partners who are, on average, older than themselves; thus the age distribution of men is not necessarily representative of the age distribution of the male partners of the women in the sample (and vice versa)."Lifetime" partners do not refer to a finite time period but to partners since first sexual intercourse "so far"; this may be the most inaccurate measure because of difficulties of recall, whereas discrepancies over shorter time intervals are much smaller.Although men and women are remarkably consistent about the frequency and type of sexual practices reported,4 strong cultural forces may nevertheless influence men and women in different ways with respect to accurate reporting of the number of sexual partners.We intend to examine this apparent anomaly more fully in future work.Francome suggests that the only way to obtain reliable data about heterosexual behaviour is to ask men about their previous experiences and the ages of their partners and from the responses construct the data for women.For those men with many partners this would require a superhuman feat of memory.More importantly, it is unaccept- able to construct data that are available by direct inquiry.John Bancroft has highlighted an important observation that recently there seems to be a greater willingness to disclose socially censured sexual behaviour.5Improved survey design (such as careful definition of a sexual partner) may result in more accurate information, but there is ample scope for further research into gender differences in reporting by detailed inquiry into the way people recollect their sexual behaviour.Increased acceptance of studies of sexual behaviour could indicate a change in the social acceptability of different lifestyles, which would lead to greater similarity between men and women in the inter- pretation of past behaviour.
Differentiation Profiling of Marrow Stem Cells: A Megakaryocytic Hotspot and the Continuum Model of Hematopoiesis
Authors: Gerald A. Colvin, Liansheng Liu, Mark Dooner, Gerri Dooner, Kevin Johnson, Elaine Papa, Jason M Aliotta, David Berz, Peter J. Quesenberry
Journal: Blood (2008)
Maladies may be linked to artists' materials
Authors: K. Glasbrenner
Journal: JAMA (1984)

Creating art rarely is easy. So the last thing that artists need are health and safety hazards to make it even tougher. Now, the School of the Art Institute in Chicago is doing something to make art safer for both the professional and the hobbiest. During the past few months, the school, in cooperation with the Metropolitan Life Foundation, New York City, launched a nationwide campaign to educate artists and craftsmen about safe work practices in the classroom and in the studio. As part of the school's "Hazards in the Arts" program, a series of booklets entitled<i>Alternatives for the Artist</i>(School of the Art Institute, Chicago, 1981) has been written by Nancy Seeger, MFA, a research consultant for the Art Institute. These guides provide information about hazards related to materials used and about precautions to take when using them. Four major disciplines are addressed: ceramics, painting, photography, and printmaking.
A Dual Role of EGFR Protein Tyrosine Kinase Signaling in Ubiquitination of AAV2 Capsids and Viral Second-strand DNA Synthesis
Authors: Li Zhong, Weihong Zhao, Jianqing Wu, Baozheng Li, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
Journal: Molecular Therapy (2007)
Treating substance-use disorders among physicians
Authors: R. E. Herrington
Journal: JAMA (1982)

Of 40 participants of a two-year program for rehabilitating alcohol- and other-drug-dependent physicians, 15 have completed 24 months of treatment and monitoring, eight have completed 12 to 23 months, ten have completed one to 11 months, and seven discontinued treatment before completion. Of the 33 treated physicians, 31 have returned to full practice and 22 have experienced no relapse. The prognosis is quite favorable for most impaired physicians if appropriate treatment, monitoring, and follow-up are provided. (<i>JAMA</i>1982;247:2253-2257)
A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma
Authors: M. Kasperek, M. Smrekar, P. Haba, C. Visser, P. Rose
Journal: Journal of Clinical Oncology (2004)

5153 Background: Topotecan is an active second-line agent for ovarian cancer but combinations with carboplatin have been limited by myeolsuppression. Weekly topotecan has been associated with less myelosuppression and moderate activity. We performed a phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma. Methods: Patients with evaluable potentially platinum sensitive ovarian or peritoneal carcinoma with PS 0–2, normal bone marrow, renal and hepatic function were eligible. Patients with a creatinine clearance of <50 cc/min by Jelliffe were excluded. Carboplatin at an AUC of 4 and in subsequent patients at an AUC of 5 with topotecan 2.0 mg/m2 was administered IV on day 1 each over 30 minutes. Topotecan at 2.0 mg/m2 was administered on days 8 and 15 provided the day of therapy ANC was ≥1,500/mcl and platelet count ≥100,000/mcl. Cycles were prescribed every 21 days. Dose escalation of topotecan was planned at 0.5 mg/m2 increments to a maximum of 4 mg/m2/week. Results: Thirteen patients were enrolled with 64 (median 5) every 21 day courses have been administered. With carboplatin at an AUC of 4, dose limiting toxicity was seen with topotecan at the starting dose of 2.0 mg/m2 and further escalation of topotecan was not possible. Since the dose limiting toxicity was neutropenia, the dose of carboplatin was elevated to an AUC of 5. This was tolerated with topotecan on day 1 and 8, but the day 15 dose was held on 43/64 (85%) of treatments due to inadequate neutrophil and/or platelet counts. Weekly topotecan on day 1 and 8 was well tolerated but in all but one patient, when day 15 topotecan was administered delays in subsequent therapy occurred. Responses have been seen in 7 of 10 evaluable patients. Conclusion: Carboplatin at an AUC of 5 in combination with topotecan at a dose of 2.0 mg/m2 on day 1and 8 is tolerable and active in potentially platinum sensitive ovarian or peritoneal carcinoma. A phase II study is planned. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline
Deficiency Disease
Authors: William B. Bean
Journal: JAMA (1960)

Occasionally the thought crosses my mind of what might happen if, say, just ten per cent of the bright young men who are following the population explosion into the cardiovascular field should take up as a lifework the study of nutrition and nutritional disease. How much better it might be for their own satisfaction and advancement as well as for the improvement of knowledge. But the glamor is wanting. Follis, who has made distinguished contributions to the pathology of deficiency disease, has produced in this book a scholarly critique in this neglected field. In this volume we get a brief but clear survey of the role played by each of the sixty-odd nutrients which must be provided the normal human being for growth, health, and reproduction. The concept that naturally occurring deficiency disease usually is caused by multiple deficiencies gets due emphasis. A section on each of the inorganic elements,